Our examination of viral and tumor antigen-specific responses revealed that the effector T cell characteristics associated with the viral response also defined the T cells responding to the encoded HER-2 tumor antigen and were further augmented in combination with CTLA-4 blockade. Here, ERBB2 is linked to neoplasm.